AVAH

Aveanna Healthcare Holdings Inc

Add to Watchlist

Advanced Chart

6.140

+0.33(5.680%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

6.4599

Open

5.830

VWAP

6.07

Vol

2.50M

Mkt Cap

1.28B

Low

5.730

Amount

15.16M

EV/EBITDA(TTM)

10.57

Total Shares

192.38M

2.55B

EV/OCF(TTM)

29.69

P/S(TTM)

0.54

Aveanna Healthcare Holdings Inc. is a provider of diversified home care platforms. Its segments include Private Duty Services (PDS), Home Health & Hospice (HHH), and Medical Solutions (MS). PDS segment includes private duty nursing (PDN) services, as well as pediatric therapy services. HHH segment includes home health services, as well as hospice and specialty program services. Its home health services involve the provision of in-home services to its patients by its clinicians, which include nurses, therapists, social workers and home health aides. Its hospice services involve a supportive philosophy and concept of care for those nearing the end of life. Medical Solutions segment offers a line of enteral nutrition supplies and other products to adults and children, delivered on a periodic or as-needed basis. It also provides case management services to assist families and patients by coordinating the provision of services between insurers and other healthcare providers.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2026Q1

FY2025Q4

FY2025Q3

588.40M

+5.22%

0.066

-33.67%

581.39M

+11.83%

0.060

+20.44%

581.94M

+14.32%

0.070

+249.6%

Estimates Revision

The market is revising Upward the revenue expectations for Aveanna Healthcare Holdings Inc. (AVAH) for FY2025, with the revenue forecasts being adjusted by 2.63% over the past three months. During the same period, the stock price has changed by 13.70%.

Revenue Estimates for FY2025

Revise Upward

+2.63%

In Past 3 Month

EPS Estimates for FY2025

Revise Upward

+48.37%

In Past 3 Month

Stock Price

Go Up

+13.70%

In Past 3 Month

5 Analyst Rating

-6.35% Downside

Wall Street analysts forecast AVAH stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for AVAH is 5.75 USD with a low forecast of 5.00 USD and a high forecast of 7.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

0 Buy

4 Hold

1 Sell

Hold

-6.35% Downside

Current: 6.140

Low

5.00

Averages

5.75

High

7.00

-6.35% Downside

Current: 6.140

Low

5.00

Averages

5.75

High

7.00

Jefferies

Hold

Buy

upgrade

2025-07-21

Reason

Jefferies

Price Target

2025-07-21

upgrade

Hold

Buy

Reason

Jefferies upgraded Aveanna to Buy from Hold with a price target of $6, down from $6.25, ahead of the Q2 report. The firm expects fundamental strength and positive earnings surprises from Aveanna due to its focus on bolstering capacity and better reimbursing payer contracts. The share selloff on the home nursing rate proposal is overdone since Medicare home health is a smaller portion of Aveanna's business, the analyst tells investors in a research note.

Truist

Hold

downgrade

$6 -> $5

2025-07-16

Reason

Truist

Price Target

$6 -> $5

2025-07-16

downgrade

Hold

Reason

Truist lowered the firm's price target on Aveanna to $5 from $6 and keeps a Hold rating on the shares as part of a broader research note previewing Q2 results for Healthcare Services. The quarter should reflect an ongoing mixed, sector-dependent backdrop across the firm's coverage universe with a focus on selectivity and utilization-leveraged names best positioned, and Managed Care continuing to face challenges, the analyst tells investors in a research note. Truist adds that it remains bullish on core demand drivers for the industry however and also believes that the Reconciliation Bill has provided increased clarity around regulatory framework.

Barclays

Equal Weight

initiated

$5.50

2025-07-02

Reason

Barclays

Price Target

$5.50

2025-07-02

initiated

Equal Weight

Reason

Barclays initiated coverage of Aveanna with an Equal Weight rating and $5.50 price target. Aveanna primarily operates in the private duty nursing business, which is a Medicaid dominant service where demand outpaces supply, the analyst tells investors. While the firm says there may be near-term earnings upside, 2026 Street EBITDA and margin forecasts \"look a bit rich\" and broader uncertainty around Medicaid policy is likely to slow rate increases, the analyst added.

UBS

Sell

maintain

2025-05-09

Reason

UBS

Price Target

2025-05-09

maintain

Sell

Reason

UBS raised the firm's price target on Aveanna to $5 from $4.50 and keeps a Sell rating on the shares. Aveanna Healthcare's Q1 results were broadly positive, the analyst tells investors in a research note.

Truist Securities

David Macdonald

Hold

Maintains

$6 → $5.5

2025-04-11

Reason

Truist Securities

David Macdonald

Price Target

$6 → $5.5

2025-04-11

Maintains

Hold

Reason

Truist lowered the firm's price target on Aveanna to $5.50 from $6 and keeps a Hold rating on the shares as part of a broader research note previewing Q1 results in Healthcare Services and adjusting the firm's models. The sector looks relatively well positioned in a fluid environment given the scaled, largely domestic, attractive free cash flow generating, defensive nature of the group, and while regulatory developments remain an area of focus, the Medicare Advantage final rule reinforced the firm's expectation of a better environment, the analyst tells investors in a research note.

UBS

A.J. Rice

Strong Sell

Maintains

$3.2 → $4.5

2025-03-14

Reason

UBS

A.J. Rice

Price Target

$3.2 → $4.5

2025-03-14

Maintains

Strong Sell

Reason

See All Ratings

Valuation Metrics

The current forward P/E ratio for Aveanna Healthcare Holdings Inc (AVAH.O) is 31.56, compared to its 5-year average forward P/E of 41.96. For a more detailed relative valuation and DCF analysis to assess Aveanna Healthcare Holdings Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

41.96

Current PE

31.56

Overvalued PE

152.47

Undervalued PE

-68.55

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

Fair

5Y Average EV/EBITDA

12.63

Current EV/EBITDA

12.54

Overvalued EV/EBITDA

14.27

Undervalued EV/EBITDA

10.99

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

Fair

5Y Average PS

0.39

Current PS

0.54

Overvalued PS

0.68

Undervalued PS

0.11